Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer
June 04 2021 - 8:00AM
Business Wire
MSK and Resolution Bioscience (a part of Agilent) investigate
clinical utility of the Resolution ctDx Lung in large prospective
cohort
Agilent Technologies Inc. (NYSE: A) today announced a
presentation by Memorial Sloan Kettering Cancer Center (MSK) at the
upcoming annual meeting of the American Society of Clinical
Oncology (ASCO) to discuss the Resolution ctDx Lung, a
laboratory-developed test (LDT) developed by Resolution
Bioscience.
The presentation titled Overall survival with circulating tumor
DNA-guided therapy in advanced non-small cell lung cancer will
present evidence for the clinical utility of Resolution ctDx Lung
in detecting actionable mutations in non-small cell lung cancer
(NSCLC) patients.
Previous findings have supported the clinical utility of the
Resolution ctDx Lung for accurately selecting patients for targeted
therapies.1 The latest study, involving the largest prospective
liquid biopsy cohort (>1,000 patients) with 3–4 years of
survival data, demonstrates that cell-free DNA guided targeted
therapies help result in better overall survival.
“This is the first and largest prospective study of ctDNA guided
therapy to show an overall survival benefit in patients with lung
cancers, providing evidence for the utility of liquid biopsy in
clinical practice,” said Bob Li, MD, PhD, MPH, Co-Director of the
Thoracic Liquid Biopsy Program at MSK.
“This large cohort highlights the utility of the Resolution ctDx
Lung in helping guide therapy selection to improve patient
outcomes,” said Mark Li, CEO of Resolution Bioscience, now a part
of Agilent. “Significantly, the study highlighted important
differences between liquid biopsies and tissue testing, including
faster turnaround to reporting, while providing the benefits of
guided targeted therapy."
The success of Resolution ctDx Lung further strengthens
Agilent's ability to deliver precision oncology testing assays for
patients worldwide and demonstrates the company's commitment as a
partner in the development of powerful new clinical diagnostics
solutions to expand the fight against cancer.
Resolution Bioscience is dedicated to developing a highly
sensitive, non-invasive liquid biopsy platform that improves cancer
diagnostics and monitoring for patients around the world. The
company has developed core technology for circulating cell-free DNA
NGS analysis. Resolution Bioscience’s Liquid Biopsy assays are
powered by the company’s cell-free DNA (cfDNA) analysis platform,
which includes targeted capture next-generation sequencing (NGS)
biochemistry and tightly coupled, cloud-based bioinformatics. The
Resolution Bioscience homologous recombination deficiency (HRD)
assay has received Breakthrough Device Designation from the U.S.
Food and Drug Administration.
References:
- Sabari JK, Offin M, Stephens D, Ni A, Lee A, et al. (2019). A
Prospective Study of Circulating Tumor DNA to Guide Matched
Targeted Therapy in Lung Cancers. Journal Of The National Cancer
Institute 111: 575-583. https://doi.org/10.1093/jnci/djy156. PMID:
30496436
About Agilent Technologies
Agilent is a leader in life sciences, diagnostics, and applied
chemical markets, delivering innovative technology solutions that
provide trusted answers to researchers’ most challenging scientific
questions. The company generated revenue of $5.34 billion in fiscal
year 2020 and employs 16,400 people worldwide. Information about
Agilent is available at www.agilent.com. To receive the latest
Agilent news, please subscribe to the Agilent Newsroom. Follow
Agilent on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210604005066/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024